Publisher： Adis International
ISSN： 1173-5503
Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.483, 2005-01, pp. : 3-4
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Adalimumab more cost effective than infliximab in early RA
Inpharma, Vol. 1, Iss. 1499, 2005-01 ,pp. :
Access to resources
Recommend
Etanercept of greater value than adalimumab or infliximab for RA
Inpharma, Vol. 1, Iss. 1614, 2007-01 ,pp. :
Etanercept of greater value than adalimumab or infliximab for RA
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 541, 2007-01 ,pp. :
Infliximab may be cost effective in severe, treatment-resistant RA
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 480, 2005-01 ,pp. :
Infliximab may be cost effective in severe, treatment-resistant RA
Inpharma, Vol. 1, Iss. 1493, 2005-01 ,pp. :